Sacral Nerve Stimulation Market Size, Share, and Industry Analysis, By Product (Devices [Internal Devices, and External Devices], and Accessories), By Application (Urinary & Fecal Incontinence, Urinary Retention, Constipation, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global sacral nerve stimulation market size was valued at USD 2.03 billion in 2025. The market is projected to grow from USD 2.29 billion in 2026 to USD 5.94 billion by 2034, exhibiting a CAGR of 12.66% during the forecast period.

The global sacral nerve stimulation market is witnessing substantial growth due to increasing cases of urinary incontinence. The sacral nerve stimulation (SNS) treatment utilizes an implantation of a neurostimulation device under the skin in the upper buttock area to send mild electric impulses to stimulate sacral nerves that control the functions of the bladder and bowels. Also, increasing market players' focus on obtaining regulatory approvals for the launch of novel sacral nerve stimulation devices globally is one of the important factors driving market growth.

• For example, in January 2023, Axonics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its fourth-generation Axonics R20 neurostimulator, a rechargeable SNM device with a 20 years or more battery life.

Moreover, the growing awareness about bladder disorders and related treatments further increases the adoption of SNS devices, thereby supplementing market growth.

Sacral Nerve Stimulation Market Driver

The Growing Aging Population is expected to Increase the Demand for Sacral Nerve Stimulation Devices, thereby Driving Market Growth

The growing aging population worldwide is significantly driving the sacral nerve stimulation market growth. As the global population ages, there is a corresponding increase in the prevalence of conditions such as urinary and fecal incontinence, which are effectively treated with sacral nerve stimulation devices.

• For instance, as per the data provided by the National Center for Biotechnology Information (NCBI) in February 2023, a cross-sectional study using cluster sampling of 433 postmenopausal women was conducted in Tabriz-Iran from 2021 to 2022. This study aimed to determine the prevalence and severity of urinary incontinence and associated risk factors in postmenopausal women. As per the study results, the overall prevalence of urinary incontinence was 39.5%.
• Additionally, as per the data provided by the United Nations in January 2023, the number of people aged 80 years and above was 155.0 million in 2021 and is estimated to increase to 459.0 million by the end of 2050.

Global Population aged 65 years and over, 2020, 2030, and 2050 (in billion)

For example, as per the data provided by the World Health Organization (WHO) in October 2024, the world population aged 65 years and over was around 1.00 billion in 2020 and is expected to increase to 2.10 billion by the end of 2050.

Sacral Nerve Stimulation Market Restraint

The High Cost of Sacral Nerve Stimulation Devices Hinders the Market Growth 

The high cost of sacral nerve stimulation (SNS) devices restricts market growth significantly, especially in the healthcare facilities of low-income countries. The SNS systems are expensive for patients in low-income countries. 

• For example, as per the data provided by Health & Hopes, the sacral nerve stimulation implants cost about USD 7,964 to USD 9,291.

Furthermore, alternative medicines are available in the market, such as anticholinergics, beta-3 adrenergic agonists, and topical estrogen for treating urinary incontinence. Also, the anti-diarrheal drugs such as loperamide (Imodium) and bismuth subsalicylate are used to treat fecal incontinence. Moreover, medications such as alpha-blockers, 5-alpha reductase inhibitors, and antibiotics are available to treat urinary retention. 

As a result, the patients of low and middle-income countries opt for cheaper alternatives like medications rather than SNS devices, thereby hindering market growth.

Sacral Nerve Stimulation Market Opportunity

The Increasing Awareness About Bladder Disorders Worldwide to Open New Opportunities for Market Growth

The increasing healthcare organizations' focus on creating awareness about urinary incontinence and related treatments worldwide is creating significant opportunities for market growth. 

• For example, the Urology Foundation organized an awareness campaign supported by Convatec on World Continence Week from 17th to 23rd June 2024. This campaign was all related to raising awareness about bladder and incontinence issues.

As awareness about bladder disorders, such as urinary and fecal incontinence, urinary retention, and constipation, rises, more individuals are anticipated to seek medical treatment for these conditions. As a result, the companies in the sacral nerve stimulation market are anticipated to experience growth opportunities in both developed and developing nations, where the awareness about SNS treatment is increasing.

Key Insights

The report covers the following key insights:

• Incidence and Prevalence of Key Chronic Diseases, by Key Countries, 2024
• New Product Launches, by Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Product

Based on the product, the market is segmented into devices and accessories. 

The devices segment is further categorized into internal devices and external devices. The devices segment is anticipated to grow at the highest CAGR from 2025 to 2032. The increasing market players' focus on receiving regulatory approvals for the launch of sacral nerve stimulation devices worldwide for treating bladder-related conditions is one of the important factors driving segmental growth during the forecast period. 

• For example, in February 2022, Medtronic announced that it had received approval from the U.S. Food and Drug Administration (FDA) for InterStim X to treat overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention.

Analysis by Application

Based on application, the market is categorized into urinary & fecal incontinence, urinary retention, constipation, and others. 

The urinary & fecal incontinence segment is anticipated to dominate the market throughout the forecast period, owing to the high burden of urinary and fecal incontinence worldwide.

• For example, as per an article published by Research Gate in January 2024, the age-standardized prevalence rates of urinary incontinence were 25.4% in women and 7.0% in men in China in 2020.

 Analysis by End-user

In terms of end-user, the market is divided into hospitals & ASCs, specialty clinics, and others. 

The hospitals & ASCs segment is projected to dominate the market during the forecast period. The hospitals and ASCs are equipped with state-of-the-art technology and skilled professionals capable of performing complex sacral nerve stimulation procedures, including implantations, thereby driving segmental growth. Also, higher hospitalization rates for the treatment of bladder disorders are further supplementing the segmental growth.

• For example, as per the data provided by the British Journal of Hospital Medicine in January 2022, acute urinary retention is a common clinical condition responsible for hospital admissions in the U.K. and is responsible for over 30,000 hospital admissions annually.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. 

Request for Customization   to gain extensive market insights.

North America accounted for the dominant share of the global sacral nerve stimulation market in 2024. The market in this region is expected to grow significantly from 2025 to 2032, owing to increasing market players' focus on receiving regulatory approvals for sacral nerve stimulators. 

• For example, in June 2025, the U.S. Food and Drug Administration (FDA) granted clearance to Neuspera Medical's integrated sacral neuromodulation (iSNM) system for the treatment of patients with urinary urge incontinence (UUI). 

Furthermore, the market growth in the region is attributed to the established healthcare infrastructure, higher healthcare spending, and high burden of bladder disorders. 

The market in Europe is anticipated to grow considerably during the forecast period. The growing aging population is more susceptible to conditions like urinary and fecal incontinence, which sacral nerve stimulation devices effectively treat, thereby driving market growth in the region.

On the other hand, the market in the Asia Pacific region is expected to grow moderately during the forecast period. The increasing market players' focus on launching sacral nerve stimulation devices is among the prominent factors driving market growth in this region. 

• For example, in November 2024, Medtronic announced the launch of the InterStim X Sacral Neuromodulation (SNM) system for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention in the Indian market.

Key Players Covered

The global sacral nerve stimulation market includes companies such as Medtronic, Axonics, Inc., Hangzhou Chengnuo Medical Technology Ltd., and Neuspera Medical. 

The report includes the profiles of the following key players:

• Medtronic (Ireland)
• Hangzhou Chengnuo Medical Technology Ltd. (China)
• Boston Scientific Corporation (U.S.)
• Axonics, Inc. (U.S.)
• Neuspera Medical (U.S.)
• Laborie (U.S.)

Key Industry Developments

• In January 2024, Boston Scientific Corporation announced entered into a definitive agreement to acquire Axonics, Inc., a medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price was USD 71 in cash per share, reflecting an equity value of approximately USD 3.70 billion and an enterprise value of approximately USD 3.40 billion.
• In June 2023, Hangzhou Chengnuo Medical Technology Ltd. announced that its three novel products, the implantable sacral nerve stimulator, implantable sacral nerve stimulation extension wire, and implantable sacral nerve stimulation electrode, were approved by the National Medical Products Administration (NMPA) for marketing of these products in China.
• In March 2021, Axonics, Inc. announced that it had entered into a strategic alliance with Micro Systems Technologies (MST), a leading manufacturer of medical microelectronics, to expand its product offering.
• In August 2020, Medtronic announced that its recently U.S. Food and Drug Administration (FDA) approved InterStim Micro neurostimulator for sacral neuromodulation (SNM) therapy is available in the U.S. market.